Dyslipidemie

Prevent the Event

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Cardiovascular diseases (CVDs) are the leading cause of death globally

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

What is PRALUENT®?

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

How to use PRALUENT®?

146 for Lipid Management After ACS

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Vergoeding Praluent

Praluent is sinds 1 juni 2016 onder nadere voorwaarden vanuit de basisverzekering vergoed. Deze voorwaarden zijn vastgelegd in Bijlage 2 van de regeling zorgverzekering.